Refine by
Microbiome Therapeutics Equipment & Supplies
14 equipment items found
Manufactured by:Moon (Guangzhou) Biotech Co.,Ltd based inHuangpu District, CHINA
From tremendous microbiome resources to precision microbe-based drug. Human microbiome is recognized as the central hub of human health and disease development and harbors tremendous microbe-based drugs for improving human health and treating diseases. MoonBiotech is moving to a clinical-stage biotech company focused on the development of innovative ...
Manufactured by:NuBiyota based inNew York, NEW YORK (USA)
Microbiome therapeutics are a novel approach to restoring equilibrium within the microbiome, which in turn can evoke the required clinical response to suppress flares or promote remission. Multiple studies have shown the efficacy of fecal microbiota transplantation (FMT) to restore gut microbiota diversity, with positive outcomes for varied ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-109 is a first-in-class investigational microbiome therapeutic administered orally following antibiotics to reduce recurrence of C. difficile infection (CDI) in patients with recurrent ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
FIN-211 is an orally administered, Enriched Consortia product candidate designed to address both the gastrointestinal (GI) and behavioral symptoms of ASD. ASD is a behaviorally defined condition characterized by difficulties with interpersonal interaction, communication, and repetitive or restrictive patterns of behavior and activities. A subset of individuals with ASD experience significant GI ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
CP101, an orally administered, Complete Consortia product candidate in late-stage clinical development for the prevention of recurrent C. difficile infection is also being developed for the treatment of chronic HBV. Chronic HBV infection occurs when the initial immune response fails to clear the virus, and may result in inflammation of hepatocytes, and complications including cirrhosis, liver ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
In collaboration with Takeda Pharmaceuticals, we are developing FIN-524 and FIN-525, orally administered, Targeted Consortia product candidates designed for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD), respectively. UC and CD are the two most common types of IBD, an autoimmune condition that causes inflammation of the gastrointestinal (GI) ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
Our lead product candidate, CP101, is an orally administered, Complete Consortia product candidate initially targeting the prevention of recurrent CDI. The Centers for Disease Control and Prevention considers CDI to be one of the top three most urgent antibiotic resistant threats and the most common cause of healthcare associated infection in the United ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-155 is an investigational, oral, rationally designed, fermented microbiome therapeutic designed to reduce the incidence of gastrointestinal infections, bacteremia, and graft versus host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-287 is an investigational, oral, biologically-derived microbiome therapeutic for the treatment of ulcerative colitis (UC). SER-287 is a consortium of multiple bacterial spores manufactured by fractionating and purifying targeted bacteria from stool of healthy human donors. SER-287 has been granted Fast Track designation and Orphan Drug designation by the ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-301 is an investigational, oral, rationally-designed, fermented microbiome therapeutic for the treatment of mild-to-moderate ulcerative colitis (UC). SER-301 is a consortium of multiple bacterial strains that is manufactured by fermenting each strain individually and then combining to form drug product. ...
Manufactured by:DermBiont, Inc. based inBoston, MASSACHUSETTS (USA)
leverage cutting edge innovation in dermatology and proprietary technology to efficiently develop targeted small molecule therapeutics and novel microbiome-based therapeutics for dermatologic indications that address the root cause of skin diseases. Our in-house discovery platform for microbiome-based ...
Manufactured by:DermBiont, Inc. based inBoston, MASSACHUSETTS (USA)
A microbe is quite simply a microscopic organism. Microbes can be single-celled or comprise clusters of cells. They even include very small animals and other multicellular organisms; many are colonial and assume forms in nature that are easily visible to the naked eye. Microbes can be classified into four discrete ...
Manufactured by:LISCure Biosciences Inc. based inSeongnam-si, SOUTH KOREA
The LMT (LISCure Microbiology-based Technology) platform is an innovative tool to keep discovering and analyzing microbial and genome-based drug candidates. LMT (LISCure Microbiology-based Technology) Platform Consists of the Therapeutic Screening Platform, Microbial Optimization Platform, and Microbiome Database ...
Manufactured by:Siolta Therapeutics based inSan Carlos, CALIFORNIA (USA)
Siolta’s Precision Symbiotics Platform enables rapid LBP development. A platform focused on translating microbiome science into novel therapeutics for a healthier world. Siolta’s patient-centric platform leverages our internal expertise in microbiome data analysis, machine learning, anaerobic microbiology, and translational studies to ...